Effects of non-surgical periodontal therapy on the cytokine profile in gingival crevicular fluid of breast cancer patients with periodontitis undergoing chemotherapy

Effect of Non-surgical Periodontal Therapy on Levels of Inflammatory Markers in Gingival Crevicular Fluid and Serum of Patients With Breast Cancer and Periodontitis.

“…This nding raises two important perspectives suggesting periodontal treatment is preferred before chemotherapy. First, the elimination of infection/in ammation foci would substantially reduce the risk of acute lesions for the patient, such as mucositis, and, consequently, bacteremia (sepsis) during the antineoplastic treatment process [14,15]. Second, and directly related to our results, would be the fact that a systemic decrease in the in ammatory mediators' levels could be understood as an important adjuvant for antitumor therapy since it has been discussed that interference in cytokinemediated signaling pathways can bring bene ts and prevent possible metastasis [12,13,20,21].…”

“…There is strong scienti c evidence of the positive impact that non-surgical periodontal therapy (NSPT), especially scaling and root planing (SRP), in the control of local and systemic infection/in ammation in normossystemic or systemically compromised patients represented by the improvement of clinical periodontal parameters, decreased count of periodontopathogenic bacteria and reduced levels of in ammatory markers in gingival crevicular uid (GCF), saliva and serum [3,4]. Recently, Vargas-Villafuerte et al [14] have shown that NSPT can reduce in ammatory markers in women with breast cancer and periodontitis, hence preventing exacerbation of the periodontal disease and sepsis in the face of immunosuppression caused by chemotherapy [15]. The reduction in serum markers achieved by the treatment of periodontitis can be understood as especially important when preceded by chemotherapy, since it could contribute to a more favorable response to antitumor therapy, thus improving the prognosis of these women.…”

Integrating Periodontal Therapy and Biofilm Management into Breast Cancer Patients' Care: Periodontal, Hematological and salivary Parameters Assessment Before and During Chemotherapy

“…The ideal sample size was calculated to ensure an 80% power to detect a signi cant difference of 10% in bleeding on probing (BOP) between the analyzed groups with a 95% con dence interval (α = 0.05) and a standard deviation (Σ) of 7.30% [11], Considering [Zα (1.96) + Zβ (0.84)]^2 = 7.84, the calculation was based on the following formula: n = {2 [(Σ)2/(δ)2]}, x (Zα + Zβ)2. Therefore, 18 patients were required for each experimental group.…”

Avaliação clínica e de mediadores inflamatórios antes e após tratamento periodontal não cirúrgico em pacientes portadoras de câncer de mama com periodontite previamente à quimioterapia

“…A diferença estatística encontrase representada pelo p<0,05. VILLAFUERTE et al, 2018;VARGAS-VILLAFUERTE et al,2021). A segunda, mais diretamente relacionada aos resultados deste estudo, seria a questão de que uma diminuição sistêmica no nível de mediadores inflamatórios poderia ser entendida como coadjuvante importante para o terapia antitumoral, uma vez que tem sido discutido que a interferência em vias de sinalização mediada por citocinas pode trazer benefícios e prevenir possíveis metástases (FABRE et al, 2018;EYRE et al, 2019;TULOTTA et al, 2019;KHOSHAKHLAGH et al, 2019;LI et al, 2020 Uma atenção especial deve ser dada a estes três marcadores inflamatórios (IL-1β, TNF-α e IL-17), uma vez que os mesmos têm sido associados a processos que levam à expansão tumoral e metástase e, consequentemente, a um pior prognóstico da neoplasia maligna da mama (CHEN et al, 2013;COFFELT et al, 2015;MARTÍNEZ-REZA et al, 2017;TULOTTA el al., 2018;CRUCERIU et al, 2020;BASTID et al, 2020).…”